 | • レポートコード：QAF27624 • 出版社/出版日：QYResearch / 2021年4月26日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、144ページ • 納品方法：Eメール（即日納品） • 産業分類：医薬品 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本市場調査資料では、世界のC-MET＆HGF阻害剤市場について種類別（カボザンチニブ、クリゾチニブ、その他）、用途別（病院、ドラッグストア）、地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2016年～2027年までの市場規模と予測（販売量、売上、価格）、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・C-MET＆HGF阻害剤市場の概要 ・世界の主要地域別C-MET＆HGF阻害剤市場規模2016-2027 ・主要プレイヤーの競争状況・市場シェア ・世界のC-MET＆HGF阻害剤市場規模2016-2021：種類別（カボザンチニブ、クリゾチニブ、その他） ・世界のC-MET＆HGF阻害剤市場予測2012-2027：種類別（カボザンチニブ、クリゾチニブ、その他） ・世界のC-MET＆HGF阻害剤市場規模2016-2021：用途別（病院、ドラッグストア） ・世界のC-MET＆HGF阻害剤市場予測2012-2027：用途別（病院、ドラッグストア） ・C-MET＆HGF阻害剤のアメリカ市場規模と予測2016-2021 ・C-MET＆HGF阻害剤のヨーロッパ市場規模と予測2016-2021 ・C-MET＆HGF阻害剤の中国市場規模と予測2016-2021 ・C-MET＆HGF阻害剤の日本市場規模と予測2016-2021 ・C-MET＆HGF阻害剤の東南アジア市場規模と予測2016-2021 ・C-MET＆HGF阻害剤のインド市場規模と予測2016-2021 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Exelixis、Ipsen、Pfizer、Novartis、Takeda、Merck KGaA、Merck、Daiichi Sankyo、GSK、Bristol-Myers Squibb(BMS)、Roche、AVEO Pharmaceuticals、Amgen、AstraZeneca、Mirati Therapeutics、Eli Lilly、Johnson & Johnson、Eisai、Hutchison MediPharma、Kringle Pharmaceuticals） ・C-MET＆HGF阻害剤の製造コスト分析 ・販売チャネル、流通業者、顧客 ・C-MET＆HGF阻害剤の市場動向・機会・課題 ・調査の結論 |
c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).
There are three kinds of C-MET / HGF Inhibitors, which are Cabozantinib, Crizotinib and Others. Cabozantinib hold the largest share of the C-MET / HGF Inhibitors market, with a revenue market share nearly 66% in 2019.
C-MET / HGF Inhibitors is sold through Hospitals and Drugs Store. The most proportion of C-MET / HGF Inhibitors is sold through Hospitals, and the market share in 2019 is about 77%.
North America is the largest consumption place, with a consumption market share nearly 60% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of about 34%.
Shandong Exelixis, Ipsen, Pfizer, etc. are the leader of the industry, and top 3 players hold about 100% revenue market share.
Market Analysis and Insights: Global C-MET & HGF Inhibitors Market
The global C-MET & HGF Inhibitors market was valued at US$ 2294.7 in 2020 and will reach US$ 8301.4 million by the end of 2027, growing at a CAGR of 23.9% during 2022-2027.
Global C-MET & HGF Inhibitors Scope and Market Size
The global C-MET & HGF Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global C-MET & HGF Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Cabozantinib
Crizotinib
Others
Segment by Application
Hospital
Drug Store
The C-MET & HGF Inhibitors market is analysed and market size information is provided by regions (countries). Segment by Application, the C-MET & HGF Inhibitors market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Exelixis
Ipsen
Pfizer
Novartis
Takeda
Merck KGaA
Merck
Daiichi Sankyo
GSK
Bristol-Myers Squibb(BMS)
Roche
AVEO Pharmaceuticals
Amgen
AstraZeneca
Mirati Therapeutics
Eli Lilly
Johnson & Johnson
Eisai
Hutchison MediPharma
Kringle Pharmaceuticals
1 C-MET & HGF Inhibitors Market Overview
1.1 C-MET & HGF Inhibitors Product Scope
1.2 C-MET & HGF Inhibitors Segment by Type
1.2.1 Global C-MET & HGF Inhibitors Sales by Type (2016 & 2021 & 2027)
1.2.2 Cabozantinib
1.2.3 Crizotinib
1.2.4 Others
1.3 C-MET & HGF Inhibitors Segment by Application
1.3.1 Global C-MET & HGF Inhibitors Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Hospital
1.3.3 Drug Store
1.4 C-MET & HGF Inhibitors Market Estimates and Forecasts (2016-2027)
1.4.1 Global C-MET & HGF Inhibitors Market Size in Value Growth Rate (2016-2027)
1.4.2 Global C-MET & HGF Inhibitors Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global C-MET & HGF Inhibitors Price Trends (2016-2027)
2 C-MET & HGF Inhibitors Estimates and Forecasts by Region
2.1 Global C-MET & HGF Inhibitors Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global C-MET & HGF Inhibitors Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global C-MET & HGF Inhibitors Sales Market Share by Region (2016-2021)
2.2.2 Global C-MET & HGF Inhibitors Revenue Market Share by Region (2016-2021)
2.3 Global C-MET & HGF Inhibitors Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global C-MET & HGF Inhibitors Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global C-MET & HGF Inhibitors Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America C-MET & HGF Inhibitors Estimates and Projections (2016-2027)
2.4.2 Europe C-MET & HGF Inhibitors Estimates and Projections (2016-2027)
2.4.3 China C-MET & HGF Inhibitors Estimates and Projections (2016-2027)
2.4.4 Japan C-MET & HGF Inhibitors Estimates and Projections (2016-2027)
2.4.5 Southeast Asia C-MET & HGF Inhibitors Estimates and Projections (2016-2027)
2.4.6 India C-MET & HGF Inhibitors Estimates and Projections (2016-2027)
3 Global C-MET & HGF Inhibitors Competition Landscape by Players
3.1 Global Top C-MET & HGF Inhibitors Players by Sales (2016-2021)
3.2 Global Top C-MET & HGF Inhibitors Players by Revenue (2016-2021)
3.3 Global C-MET & HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in C-MET & HGF Inhibitors as of 2020)
3.4 Global C-MET & HGF Inhibitors Average Price by Company (2016-2021)
3.5 Manufacturers C-MET & HGF Inhibitors Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global C-MET & HGF Inhibitors Market Size by Type
4.1 Global C-MET & HGF Inhibitors Historic Market Review by Type (2016-2021)
4.1.1 Global C-MET & HGF Inhibitors Sales Market Share by Type (2016-2021)
4.1.2 Global C-MET & HGF Inhibitors Revenue Market Share by Type (2016-2021)
4.1.3 Global C-MET & HGF Inhibitors Price by Type (2016-2021)
4.2 Global C-MET & HGF Inhibitors Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global C-MET & HGF Inhibitors Sales Forecast by Type (2022-2027)
4.2.2 Global C-MET & HGF Inhibitors Revenue Forecast by Type (2022-2027)
4.2.3 Global C-MET & HGF Inhibitors Price Forecast by Type (2022-2027)
5 Global C-MET & HGF Inhibitors Market Size by Application
5.1 Global C-MET & HGF Inhibitors Historic Market Review by Application (2016-2021)
5.1.1 Global C-MET & HGF Inhibitors Sales Market Share by Application (2016-2021)
5.1.2 Global C-MET & HGF Inhibitors Revenue Market Share by Application (2016-2021)
5.1.3 Global C-MET & HGF Inhibitors Price by Application (2016-2021)
5.2 Global C-MET & HGF Inhibitors Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global C-MET & HGF Inhibitors Sales Forecast by Application (2022-2027)
5.2.2 Global C-MET & HGF Inhibitors Revenue Forecast by Application (2022-2027)
5.2.3 Global C-MET & HGF Inhibitors Price Forecast by Application (2022-2027)
6 North America C-MET & HGF Inhibitors Market Facts & Figures
6.1 North America C-MET & HGF Inhibitors Sales by Company
6.1.1 North America C-MET & HGF Inhibitors Sales by Company (2016-2021)
6.1.2 North America C-MET & HGF Inhibitors Revenue by Company (2016-2021)
6.2 North America C-MET & HGF Inhibitors Sales Breakdown by Type
6.2.1 North America C-MET & HGF Inhibitors Sales Breakdown by Type (2016-2021)
6.2.2 North America C-MET & HGF Inhibitors Sales Breakdown by Type (2022-2027)
6.3 North America C-MET & HGF Inhibitors Sales Breakdown by Application
6.3.1 North America C-MET & HGF Inhibitors Sales Breakdown by Application (2016-2021)
6.3.2 North America C-MET & HGF Inhibitors Sales Breakdown by Application (2022-2027)
7 Europe C-MET & HGF Inhibitors Market Facts & Figures
7.1 Europe C-MET & HGF Inhibitors Sales by Company
7.1.1 Europe C-MET & HGF Inhibitors Sales by Company (2016-2021)
7.1.2 Europe C-MET & HGF Inhibitors Revenue by Company (2016-2021)
7.2 Europe C-MET & HGF Inhibitors Sales Breakdown by Type
7.2.1 Europe C-MET & HGF Inhibitors Sales Breakdown by Type (2016-2021)
7.2.2 Europe C-MET & HGF Inhibitors Sales Breakdown by Type (2022-2027)
7.3 Europe C-MET & HGF Inhibitors Sales Breakdown by Application
7.3.1 Europe 144 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 144 Sales Breakdown by Application (2022-2027)
8 China C-MET & HGF Inhibitors Market Facts & Figures
8.1 China C-MET & HGF Inhibitors Sales by Company
8.1.1 China C-MET & HGF Inhibitors Sales by Company (2016-2021)
8.1.2 China C-MET & HGF Inhibitors Revenue by Company (2016-2021)
8.2 China C-MET & HGF Inhibitors Sales Breakdown by Type
8.2.1 China C-MET & HGF Inhibitors Sales Breakdown by Type (2016-2021)
8.2.2 China C-MET & HGF Inhibitors Sales Breakdown by Type (2022-2027)
8.3 China C-MET & HGF Inhibitors Sales Breakdown by Application
8.3.1 China 311 Sales Breakdown by Application (2016-2021)
8.3.2 China 311 Sales Breakdown by Application (2022-2027)
9 Japan C-MET & HGF Inhibitors Market Facts & Figures
9.1 Japan C-MET & HGF Inhibitors Sales by Company
9.1.1 Japan C-MET & HGF Inhibitors Sales by Company (2016-2021)
9.1.2 Japan C-MET & HGF Inhibitors Revenue by Company (2016-2021)
9.2 Japan C-MET & HGF Inhibitors Sales Breakdown by Type
9.2.1 Japan C-MET & HGF Inhibitors Sales Breakdown by Type (2016-2021)
9.2.2 Japan C-MET & HGF Inhibitors Sales Breakdown by Type (2022-2027)
9.3 Japan C-MET & HGF Inhibitors Sales Breakdown by Application
9.3.1 Japan Jan. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Jan. Sales Breakdown by Application (2022-2027)
10 Southeast Asia C-MET & HGF Inhibitors Market Facts & Figures
10.1 Southeast Asia C-MET & HGF Inhibitors Sales by Company
10.1.1 Southeast Asia C-MET & HGF Inhibitors Sales by Company (2016-2021)
10.1.2 Southeast Asia C-MET & HGF Inhibitors Revenue by Company (2016-2021)
10.2 Southeast Asia C-MET & HGF Inhibitors Sales Breakdown by Type
10.2.1 Southeast Asia C-MET & HGF Inhibitors Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia C-MET & HGF Inhibitors Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia C-MET & HGF Inhibitors Sales Breakdown by Application
10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)
11 India C-MET & HGF Inhibitors Market Facts & Figures
11.1 India C-MET & HGF Inhibitors Sales by Company
11.1.1 India C-MET & HGF Inhibitors Sales by Company (2016-2021)
11.1.2 India C-MET & HGF Inhibitors Revenue by Company (2016-2021)
11.2 India C-MET & HGF Inhibitors Sales Breakdown by Type
11.2.1 India C-MET & HGF Inhibitors Sales Breakdown by Type (2016-2021)
11.2.2 India C-MET & HGF Inhibitors Sales Breakdown by Type (2022-2027)
11.3 India C-MET & HGF Inhibitors Sales Breakdown by Application
11.3.1 India C-MET & HGF Inhibitors Sales Breakdown by Application (2016-2021)
11.3.2 India C-MET & HGF Inhibitors Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in C-MET & HGF Inhibitors Business
12.1 Exelixis
12.1.1 Exelixis Corporation Information
12.1.2 Exelixis Business Overview
12.1.3 Exelixis C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Exelixis C-MET & HGF Inhibitors Products Offered
12.1.5 Exelixis Recent Development
12.2 Ipsen
12.2.1 Ipsen Corporation Information
12.2.2 Ipsen Business Overview
12.2.3 Ipsen C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Ipsen C-MET & HGF Inhibitors Products Offered
12.2.5 Ipsen Recent Development
12.3 Pfizer
12.3.1 Pfizer Corporation Information
12.3.2 Pfizer Business Overview
12.3.3 Pfizer C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Pfizer C-MET & HGF Inhibitors Products Offered
12.3.5 Pfizer Recent Development
12.4 Novartis
12.4.1 Novartis Corporation Information
12.4.2 Novartis Business Overview
12.4.3 Novartis C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Novartis C-MET & HGF Inhibitors Products Offered
12.4.5 Novartis Recent Development
12.5 Takeda
12.5.1 Takeda Corporation Information
12.5.2 Takeda Business Overview
12.5.3 Takeda C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Takeda C-MET & HGF Inhibitors Products Offered
12.5.5 Takeda Recent Development
12.6 Merck KGaA
12.6.1 Merck KGaA Corporation Information
12.6.2 Merck KGaA Business Overview
12.6.3 Merck KGaA C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Merck KGaA C-MET & HGF Inhibitors Products Offered
12.6.5 Merck KGaA Recent Development
12.7 Merck
12.7.1 Merck Corporation Information
12.7.2 Merck Business Overview
12.7.3 Merck C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Merck C-MET & HGF Inhibitors Products Offered
12.7.5 Merck Recent Development
12.8 Daiichi Sankyo
12.8.1 Daiichi Sankyo Corporation Information
12.8.2 Daiichi Sankyo Business Overview
12.8.3 Daiichi Sankyo C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Daiichi Sankyo C-MET & HGF Inhibitors Products Offered
12.8.5 Daiichi Sankyo Recent Development
12.9 GSK
12.9.1 GSK Corporation Information
12.9.2 GSK Business Overview
12.9.3 GSK C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.9.4 GSK C-MET & HGF Inhibitors Products Offered
12.9.5 GSK Recent Development
12.10 Bristol-Myers Squibb(BMS)
12.10.1 Bristol-Myers Squibb(BMS) Corporation Information
12.10.2 Bristol-Myers Squibb(BMS) Business Overview
12.10.3 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Products Offered
12.10.5 Bristol-Myers Squibb(BMS) Recent Development
12.11 Roche
12.11.1 Roche Corporation Information
12.11.2 Roche Business Overview
12.11.3 Roche C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Roche C-MET & HGF Inhibitors Products Offered
12.11.5 Roche Recent Development
12.12 AVEO Pharmaceuticals
12.12.1 AVEO Pharmaceuticals Corporation Information
12.12.2 AVEO Pharmaceuticals Business Overview
12.12.3 AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.12.4 AVEO Pharmaceuticals C-MET & HGF Inhibitors Products Offered
12.12.5 AVEO Pharmaceuticals Recent Development
12.13 Amgen
12.13.1 Amgen Corporation Information
12.13.2 Amgen Business Overview
12.13.3 Amgen C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Amgen C-MET & HGF Inhibitors Products Offered
12.13.5 Amgen Recent Development
12.14 AstraZeneca
12.14.1 AstraZeneca Corporation Information
12.14.2 AstraZeneca Business Overview
12.14.3 AstraZeneca C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.14.4 AstraZeneca C-MET & HGF Inhibitors Products Offered
12.14.5 AstraZeneca Recent Development
12.15 Mirati Therapeutics
12.15.1 Mirati Therapeutics Corporation Information
12.15.2 Mirati Therapeutics Business Overview
12.15.3 Mirati Therapeutics C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Mirati Therapeutics C-MET & HGF Inhibitors Products Offered
12.15.5 Mirati Therapeutics Recent Development
12.16 Eli Lilly
12.16.1 Eli Lilly Corporation Information
12.16.2 Eli Lilly Business Overview
12.16.3 Eli Lilly C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.16.4 Eli Lilly C-MET & HGF Inhibitors Products Offered
12.16.5 Eli Lilly Recent Development
12.17 Johnson & Johnson
12.17.1 Johnson & Johnson Corporation Information
12.17.2 Johnson & Johnson Business Overview
12.17.3 Johnson & Johnson C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.17.4 Johnson & Johnson C-MET & HGF Inhibitors Products Offered
12.17.5 Johnson & Johnson Recent Development
12.18 Eisai
12.18.1 Eisai Corporation Information
12.18.2 Eisai Business Overview
12.18.3 Eisai C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.18.4 Eisai C-MET & HGF Inhibitors Products Offered
12.18.5 Eisai Recent Development
12.19 Hutchison MediPharma
12.19.1 Hutchison MediPharma Corporation Information
12.19.2 Hutchison MediPharma Business Overview
12.19.3 Hutchison MediPharma C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.19.4 Hutchison MediPharma C-MET & HGF Inhibitors Products Offered
12.19.5 Hutchison MediPharma Recent Development
12.20 Kringle Pharmaceuticals
12.20.1 Kringle Pharmaceuticals Corporation Information
12.20.2 Kringle Pharmaceuticals Business Overview
12.20.3 Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.20.4 Kringle Pharmaceuticals C-MET & HGF Inhibitors Products Offered
12.20.5 Kringle Pharmaceuticals Recent Development
13 C-MET & HGF Inhibitors Manufacturing Cost Analysis
13.1 C-MET & HGF Inhibitors Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of C-MET & HGF Inhibitors
13.4 C-MET & HGF Inhibitors Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 C-MET & HGF Inhibitors Distributors List
14.3 C-MET & HGF Inhibitors Customers
15 Market Dynamics
15.1 C-MET & HGF Inhibitors Market Trends
15.2 C-MET & HGF Inhibitors Drivers
15.3 C-MET & HGF Inhibitors Market Challenges
15.4 C-MET & HGF Inhibitors Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global C-MET & HGF Inhibitors Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global C-MET & HGF Inhibitors Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global C-MET & HGF Inhibitors Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global C-MET & HGF Inhibitors Sales (K Units) by Region (2016-2021)
Table 5. Global C-MET & HGF Inhibitors Sales Market Share by Region (2016-2021)
Table 6. Global C-MET & HGF Inhibitors Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global C-MET & HGF Inhibitors Revenue Share by Region (2016-2021)
Table 8. Global C-MET & HGF Inhibitors Sales (K Units) Forecast by Region (2022-2027)
Table 9. Global C-MET & HGF Inhibitors Sales Market Share Forecast by Region (2022-2027)
Table 10. Global C-MET & HGF Inhibitors Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global C-MET & HGF Inhibitors Revenue Share Forecast by Region (2022-2027)
Table 12. Global C-MET & HGF Inhibitors Sales (K Units) of Key Companies (2016-2021)
Table 13. Global C-MET & HGF Inhibitors Sales Share by Company (2016-2021)
Table 14. Global C-MET & HGF Inhibitors Revenue (US$ Million) by Company (2016-2021)
Table 15. Global C-MET & HGF Inhibitors Revenue Share by Company (2016-2021)
Table 16. Global C-MET & HGF Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in C-MET & HGF Inhibitors as of 2020)
Table 17. Global C-MET & HGF Inhibitors Average Price (US$/Unit) of Key Company (2016-2021)
Table 18. Manufacturers C-MET & HGF Inhibitors Manufacturing Sites and Area Served
Table 19. Manufacturers C-MET & HGF Inhibitors Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global C-MET & HGF Inhibitors Sales (K Units) by Type (2016-2021)
Table 22. Global C-MET & HGF Inhibitors Sales Share by Type (2016-2021)
Table 23. Global C-MET & HGF Inhibitors Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global C-MET & HGF Inhibitors Price (US$/Unit) by Type (2016-2021)
Table 25. Global C-MET & HGF Inhibitors Sales Share by Type (2022-2027)
Table 26. Global C-MET & HGF Inhibitors Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global C-MET & HGF Inhibitors Revenue Share by Type (2022-2027)
Table 28. Global C-MET & HGF Inhibitors Price (US$/Unit) by Type (2022-2027)
Table 29. Global C-MET & HGF Inhibitors Sales (K Units) by Application (2016-2021)
Table 30. Global C-MET & HGF Inhibitors Sales Share by Application (2016-2021)
Table 31. Global C-MET & HGF Inhibitors Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global C-MET & HGF Inhibitors Price (US$/Unit) by Application (2016-2021)
Table 33. Global C-MET & HGF Inhibitors Sales (K Units) by Application (2022-2027)
Table 34. Global C-MET & HGF Inhibitors Sales Share by Application (2022-2027)
Table 35. Global C-MET & HGF Inhibitors Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global C-MET & HGF Inhibitors Revenue Share by Application (2022-2027)
Table 37. Global C-MET & HGF Inhibitors Price (US$/Unit) by Application (2022-2027)
Table 38. North America C-MET & HGF Inhibitors Sales (K Units) by Company (2016-2021)
Table 39. North America C-MET & HGF Inhibitors Sales Market Share by Company (2016-2021)
Table 40. North America C-MET & HGF Inhibitors Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America C-MET & HGF Inhibitors Revenue Market Share by Company (2016-2021)
Table 42. North America C-MET & HGF Inhibitors Sales by Type (2016-2021) & (K Units)
Table 43. North America C-MET & HGF Inhibitors Sales Market Share by Type (2016-2021)
Table 44. North America C-MET & HGF Inhibitors Sales by Type (2022-2027) & (K Units)
Table 45. North America C-MET & HGF Inhibitors Sales Market Share by Type (2022-2027)
Table 46. North America C-MET & HGF Inhibitors Sales by Application (2016-2021) & (K Units)
Table 47. North America C-MET & HGF Inhibitors Sales Market Share by Application (2016-2021)
Table 48. North America C-MET & HGF Inhibitors Sales by Application (2022-2027) & (K Units)
Table 49. North America C-MET & HGF Inhibitors Sales Market Share by Application (2022-2027)
Table 50. Europe C-MET & HGF Inhibitors Sales (K Units) by Company (2016-2021)
Table 51. Europe C-MET & HGF Inhibitors Sales Market Share by Company (2016-2021)
Table 52. Europe C-MET & HGF Inhibitors Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe C-MET & HGF Inhibitors Revenue Market Share by Company (2016-2021)
Table 54. Europe C-MET & HGF Inhibitors Sales by Type (2016-2021) & (K Units)
Table 55. Europe C-MET & HGF Inhibitors Sales Market Share by Type (2016-2021)
Table 56. Europe C-MET & HGF Inhibitors Sales by Type (2022-2027) & (K Units)
Table 57. Europe C-MET & HGF Inhibitors Sales Market Share by Type (2022-2027)
Table 58. Europe C-MET & HGF Inhibitors Sales by Application (2016-2021) & (K Units)
Table 59. Europe C-MET & HGF Inhibitors Sales Market Share by Application (2016-2021)
Table 60. Europe C-MET & HGF Inhibitors Sales by Application (2022-2027) & (K Units)
Table 61. Europe C-MET & HGF Inhibitors Sales Market Share by Application (2022-2027)
Table 62. China C-MET & HGF Inhibitors Sales (K Units) by Company (2016-2021)
Table 63. China C-MET & HGF Inhibitors Sales Market Share by Company (2016-2021)
Table 64. China C-MET & HGF Inhibitors Revenue by Company (2016-2021) & (US$ Million)
Table 65. China C-MET & HGF Inhibitors Revenue Market Share by Company (2016-2021)
Table 66. China C-MET & HGF Inhibitors Sales by Type (2016-2021) & (K Units)
Table 67. China C-MET & HGF Inhibitors Sales Market Share by Type (2016-2021)
Table 68. China C-MET & HGF Inhibitors Sales by Type (2022-2027) & (K Units)
Table 69. China C-MET & HGF Inhibitors Sales Market Share by Type (2022-2027)
Table 70. China C-MET & HGF Inhibitors Sales by Application (2016-2021) & (K Units)
Table 71. China C-MET & HGF Inhibitors Sales Market Share by Application (2016-2021)
Table 72. China C-MET & HGF Inhibitors Sales by Application (2022-2027) & (K Units)
Table 73. China C-MET & HGF Inhibitors Sales Market Share by Application (2022-2027)
Table 74. Japan C-MET & HGF Inhibitors Sales (K Units) by Company (2016-2021)
Table 75. Japan C-MET & HGF Inhibitors Sales Market Share by Company (2016-2021)
Table 76. Japan C-MET & HGF Inhibitors Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan C-MET & HGF Inhibitors Revenue Market Share by Company (2016-2021)
Table 78. Japan C-MET & HGF Inhibitors Sales by Type (2016-2021) & (K Units)
Table 79. Japan C-MET & HGF Inhibitors Sales Market Share by Type (2016-2021)
Table 80. Japan C-MET & HGF Inhibitors Sales by Type (2022-2027) & (K Units)
Table 81. Japan C-MET & HGF Inhibitors Sales Market Share by Type (2022-2027)
Table 82. Japan C-MET & HGF Inhibitors Sales by Application (2016-2021) & (K Units)
Table 83. Japan C-MET & HGF Inhibitors Sales Market Share by Application (2016-2021)
Table 84. Japan C-MET & HGF Inhibitors Sales by Application (2022-2027) & (K Units)
Table 85. Japan C-MET & HGF Inhibitors Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia C-MET & HGF Inhibitors Sales (K Units) by Company (2016-2021)
Table 87. Southeast Asia C-MET & HGF Inhibitors Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia C-MET & HGF Inhibitors Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia C-MET & HGF Inhibitors Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia C-MET & HGF Inhibitors Sales by Type (2016-2021) & (K Units)
Table 91. Southeast Asia C-MET & HGF Inhibitors Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia C-MET & HGF Inhibitors Sales by Type (2022-2027) & (K Units)
Table 93. Southeast Asia C-MET & HGF Inhibitors Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia C-MET & HGF Inhibitors Sales by Application (2016-2021) & (K Units)
Table 95. Southeast Asia C-MET & HGF Inhibitors Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia C-MET & HGF Inhibitors Sales by Application (2022-2027) & (K Units)
Table 97. Southeast Asia C-MET & HGF Inhibitors Sales Market Share by Application (2022-2027)
Table 98. India C-MET & HGF Inhibitors Sales (K Units) by Company (2016-2021)
Table 99. India C-MET & HGF Inhibitors Sales Market Share by Company (2016-2021)
Table 100. India C-MET & HGF Inhibitors Revenue by Company (2016-2021) & (US$ Million)
Table 101. India C-MET & HGF Inhibitors Revenue Market Share by Company (2016-2021)
Table 102. India C-MET & HGF Inhibitors Sales by Type (2016-2021) & (K Units)
Table 103. India C-MET & HGF Inhibitors Sales Market Share by Type (2016-2021)
Table 104. India C-MET & HGF Inhibitors Sales by Type (2022-2027) & (K Units)
Table 105. India C-MET & HGF Inhibitors Sales Market Share by Type (2022-2027)
Table 106. India C-MET & HGF Inhibitors Sales by Application (2016-2021) & (K Units)
Table 107. India C-MET & HGF Inhibitors Sales Market Share by Application (2016-2021)
Table 108. India C-MET & HGF Inhibitors Sales by Application (2022-2027) & (K Units)
Table 109. India C-MET & HGF Inhibitors Sales Market Share by Application (2022-2027)
Table 110. Exelixis Corporation Information
Table 111. Exelixis Description and Business Overview
Table 112. Exelixis C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 113. Exelixis C-MET & HGF Inhibitors Product
Table 114. Exelixis Recent Development
Table 115. Ipsen Corporation Information
Table 116. Ipsen Description and Business Overview
Table 117. Ipsen C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 118. Ipsen C-MET & HGF Inhibitors Product
Table 119. Ipsen Recent Development
Table 120. Pfizer Corporation Information
Table 121. Pfizer Description and Business Overview
Table 122. Pfizer C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 123. Pfizer C-MET & HGF Inhibitors Product
Table 124. Pfizer Recent Development
Table 125. Novartis Corporation Information
Table 126. Novartis Description and Business Overview
Table 127. Novartis C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 128. Novartis C-MET & HGF Inhibitors Product
Table 129. Novartis Recent Development
Table 130. Takeda Corporation Information
Table 131. Takeda Description and Business Overview
Table 132. Takeda C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 133. Takeda C-MET & HGF Inhibitors Product
Table 134. Takeda Recent Development
Table 135. Merck KGaA Corporation Information
Table 136. Merck KGaA Description and Business Overview
Table 137. Merck KGaA C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 138. Merck KGaA C-MET & HGF Inhibitors Product
Table 139. Merck KGaA Recent Development
Table 140. Merck Corporation Information
Table 141. Merck Description and Business Overview
Table 142. Merck C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 143. Merck C-MET & HGF Inhibitors Product
Table 144. Merck Recent Development
Table 145. Daiichi Sankyo Corporation Information
Table 146. Daiichi Sankyo C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 147. Daiichi Sankyo Description and Business Overview
Table 148. Daiichi Sankyo C-MET & HGF Inhibitors Product
Table 149. Daiichi Sankyo Recent Development
Table 150. GSK Corporation Information
Table 151. GSK C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 152. GSK Description and Business Overview
Table 153. GSK C-MET & HGF Inhibitors Product
Table 154. GSK Recent Development
Table 155. Bristol-Myers Squibb(BMS) Corporation Information
Table 156. Bristol-Myers Squibb(BMS) Description and Business Overview
Table 157. Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 158. Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product
Table 159. Bristol-Myers Squibb(BMS) Recent Development
Table 160. Roche Corporation Information
Table 161. Roche Description and Business Overview
Table 162. Roche C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 163. Roche C-MET & HGF Inhibitors Product
Table 164. Roche Recent Development
Table 165. AVEO Pharmaceuticals Corporation Information
Table 166. AVEO Pharmaceuticals Description and Business Overview
Table 167. AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 168. AVEO Pharmaceuticals C-MET & HGF Inhibitors Product
Table 169. AVEO Pharmaceuticals Recent Development
Table 170. Amgen Corporation Information
Table 171. Amgen Description and Business Overview
Table 172. Amgen C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 173. Amgen C-MET & HGF Inhibitors Product
Table 174. Amgen Recent Development
Table 175. AstraZeneca Corporation Information
Table 176. AstraZeneca Description and Business Overview
Table 177. AstraZeneca C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 178. AstraZeneca C-MET & HGF Inhibitors Product
Table 179. AstraZeneca Recent Development
Table 180. Mirati Therapeutics Corporation Information
Table 181. Mirati Therapeutics Description and Business Overview
Table 182. Mirati Therapeutics C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 183. Mirati Therapeutics C-MET & HGF Inhibitors Product
Table 184. Mirati Therapeutics Recent Development
Table 185. Eli Lilly Corporation Information
Table 186. Eli Lilly Description and Business Overview
Table 187. Eli Lilly C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 188. Eli Lilly C-MET & HGF Inhibitors Product
Table 189. Eli Lilly Recent Development
Table 190. Johnson & Johnson Corporation Information
Table 191. Johnson & Johnson Description and Business Overview
Table 192. Johnson & Johnson C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 193. Johnson & Johnson C-MET & HGF Inhibitors Product
Table 194. Johnson & Johnson Recent Development
Table 195. Eisai Corporation Information
Table 196. Eisai Description and Business Overview
Table 197. Eisai C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 198. Eisai C-MET & HGF Inhibitors Product
Table 199. Eisai Recent Development
Table 200. Hutchison MediPharma Corporation Information
Table 201. Hutchison MediPharma Description and Business Overview
Table 202. Hutchison MediPharma C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 203. Hutchison MediPharma C-MET & HGF Inhibitors Product
Table 204. Hutchison MediPharma Recent Development
Table 205. Kringle Pharmaceuticals Corporation Information
Table 206. Kringle Pharmaceuticals Description and Business Overview
Table 207. Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 208. Kringle Pharmaceuticals C-MET & HGF Inhibitors Product
Table 209. Kringle Pharmaceuticals Recent Development
Table 210. Production Base and Market Concentration Rate of Raw Material
Table 211. Key Suppliers of Raw Materials
Table 212. C-MET & HGF Inhibitors Distributors List
Table 213. C-MET & HGF Inhibitors Customers List
Table 214. C-MET & HGF Inhibitors Market Trends
Table 215. C-MET & HGF Inhibitors Market Drivers
Table 216. C-MET & HGF Inhibitors Market Challenges
Table 217. C-MET & HGF Inhibitors Market Restraints
Table 218. Research Programs/Design for This Report
Table 219. Key Data Information from Secondary Sources
Table 220. Key Data Information from Primary Sources
List of Figures
Figure 1. C-MET & HGF Inhibitors Product Picture
Figure 2. Global C-MET & HGF Inhibitors Sales Market Share by Type in 2021 & 2027
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global C-MET & HGF Inhibitors Sales Market Share by Application in 2021 & 2027
Figure 6. Hospital Examples
Figure 7. Drug Store Examples
Figure 8. Global C-MET & HGF Inhibitors Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 9. Global C-MET & HGF Inhibitors Sales Growth Rate (2016-2027) & (US$ Million)
Figure 10. Global C-MET & HGF Inhibitors Sales (K Units) Growth Rate (2016-2027)
Figure 11. Global C-MET & HGF Inhibitors Price Trends Growth Rate (2016-2027) (US$/Unit)
Figure 12. Global C-MET & HGF Inhibitors Revenue Market Share by Region: 2016 VS 2021
Figure 13. Global C-MET & HGF Inhibitors Revenue Market Share by Region: 2021 VS 2027
Figure 14. North America C-MET & HGF Inhibitors Revenue (Million USD) Growth Rate (2016-2027)
Figure 15. North America C-MET & HGF Inhibitors Sales (K Units) Growth Rate (2016-2027)
Figure 16. Europe C-MET & HGF Inhibitors Revenue (Million USD) Growth Rate (2016-2027)
Figure 17. Europe C-MET & HGF Inhibitors Sales (Million USD) Growth Rate (2016-2027)
Figure 18. China C-MET & HGF Inhibitors Revenue (Million USD) Growth Rate (2016-2027)
Figure 19. China C-MET & HGF Inhibitors Sales (Million USD) and Growth Rate (2016-2027)
Figure 20. Japan C-MET & HGF Inhibitors Revenue (Million USD) Growth Rate (2016-2027)
Figure 21. Japan C-MET & HGF Inhibitors Sales (Million USD) Growth Rate (2016-2027)
Figure 22. Southeast Asia C-MET & HGF Inhibitors Revenue (Million USD) Growth Rate (2016-2027)
Figure 23. Southeast Asia C-MET & HGF Inhibitors Sales (Million USD) Growth Rate (2016-2027)
Figure 24. India C-MET & HGF Inhibitors Revenue (Million USD) Growth Rate (2016-2027)
Figure 25. India C-MET & HGF Inhibitors Sales (Million USD) Growth Rate (2016-2027)
Figure 26. Global 5 Largest C-MET & HGF Inhibitors Players Market Share by Revenue in C-MET & HGF Inhibitors: 2016 & 2020
Figure 27. C-MET & HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 28. Global C-MET & HGF Inhibitors Revenue Share by Type (2016-2021)
Figure 29. Global C-MET & HGF Inhibitors Revenue Growth Rate by Type in 2016 & 2020
Figure 30. Global C-MET & HGF Inhibitors Revenue Share by Application (2016-2021)
Figure 31. Global C-MET & HGF Inhibitors Revenue Growth Rate by Application in 2016 & 2020
Figure 32. North America C-MET & HGF Inhibitors Sales Market Share by Type in 2020
Figure 33. North America C-MET & HGF Inhibitors Sales Market Share by Application in 2020
Figure 34. Europe C-MET & HGF Inhibitors Sales Market Share by Type in 2020
Figure 35. Europe C-MET & HGF Inhibitors Sales Market Share by Application in 2020
Figure 36. China C-MET & HGF Inhibitors Sales Market Share by Type in 2020
Figure 37. China C-MET & HGF Inhibitors Sales Market Share by Application in 2020
Figure 38. Japan C-MET & HGF Inhibitors Sales Market Share by Type in 2020
Figure 39. Japan C-MET & HGF Inhibitors Sales Market Share by Application in 2020
Figure 40. Southeast Asia C-MET & HGF Inhibitors Sales Market Share by Type in 2020
Figure 41. Southeast Asia C-MET & HGF Inhibitors Sales Market Share by Application in 2020
Figure 42. India C-MET & HGF Inhibitors Sales Market Share by Type in 2020
Figure 43. India C-MET & HGF Inhibitors Sales Market Share by Application in 2020
Figure 44. Key Raw Materials Price Trend
Figure 45. Manufacturing Cost Structure of C-MET & HGF Inhibitors
Figure 46. Manufacturing Process Analysis of C-MET & HGF Inhibitors
Figure 47. C-MET & HGF Inhibitors Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
世界のノイラミニダーゼ阻害薬市場規模・現状・予測（2021年-2027年） Neuraminidase Inhibitors (NAIs) are the type of drugs that are used to block the neuraminidase enzyme. Market Analysis and Insights: Global Neuraminidase Inhibitors Drug Market The global Neuraminidase Inhibitors Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2…- 世界のBCL-2（B細胞リンパ腫2）阻害剤市場規模・現状・予測（2021年-2027年） Bcl-2 (B-cell lymphoma 2), encoded in humans by the BCL2 gene, is the founding member of the Bcl-2 family of regulator proteins that regulate cell death (apoptosis), by either inhibiting (anti-apoptotic) or inducing (pro-apoptotic) apoptosis. Market Analysis and Insights: Global BCL-2 (B-cell lympho…
- 世界の副腎皮質ホルモン阻害剤市場規模・現状・予測（2021年-2027年） Adrenal corticosteroid inhibitors are a class of therapeutic drugs that are widely used to treat Cushing's syndrome and certain types of solid tumors, such as breast cancer. It exerts its effect by inhibiting the endogenous synthesis of hormones secreted by the adrenal cortex by interfering with the…
- 世界のヤヌスキナーゼ（JAK）阻害剤市場規模・現状・予測（2021年-2027年） JAK inhibitors are increasingly being used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis because of its proven efficacy in the treatment of various chronic diseases. The high unmet need for the treatment of graft-versus-host disease (GVHD) has also encouraged market vend…
- 世界のPI3キナーゼ（PI3K）阻害剤市場規模・現状・予測（2021年-2027年） PI3K inhibitors work by inhibiting PI3K enzymes, which helps in signaling the pathway for cellular functions such as growth control, metabolism, and translation initiation. There is extensive ongoing research on targeted therapies such as PI3K inhibitors with proven efficacy in oncology applications…